CSIMarket
 
Cellectar Biosciences Inc   (CLRB)
Other Ticker:  
 
 
Price: $2.0300 $-0.01 -0.490%
Day's High: $2.07 Week Perf: -0.98 %
Day's Low: $ 1.98 30 Day Perf: -6.02 %
Volume (M): 139 52 Wk High: $ 4.45
Volume (M$): $ 282 52 Wk Avg: $2.81
Open: $1.98 52 Wk Low: $1.82



 Market Capitalization (Millions $) 76
 Shares Outstanding (Millions) 37
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -62
 Cash Flow (TTM) (Millions $) 24
 Capital Exp. (TTM) (Millions $) 1

Cellectar Biosciences Inc
Cellectar Biosciences Inc. is a clinical-stage biopharmaceutical company that develops targeted drugs for the treatment of cancer. The company primarily focuses on developing novel phospholipid drug conjugates (PDCs), which deliver potent therapeutic agents selectively to cancer cells. Cellectar's PDC platform has the potential to improve the efficacy and safety of current cancer treatments by increasing tumor targeting while reducing damage to healthy cells.

Cellectar's lead product candidate, CLR 131, is being evaluated in multiple Phase 2 clinical trials for various types of cancer, including multiple myeloma, lymphoma, and pediatric solid tumors. CLR 131 targets cancer cells by binding to specific receptors on their surface and delivers a radioactive isotope directly to the tumor, resulting in targeted killing of cancer cells.

In addition to CLR 131, Cellectar has a robust pipeline of other PDC candidates in preclinical development, targeting different types of cancer. The company continues to invest in research and development to expand its product portfolio and explore the potential applications of its innovative technology.

Overall, Cellectar Biosciences Inc. is dedicated to developing targeted therapies that can significantly improve the outcomes and quality of life for cancer patients.


   Company Address: 100 Campus Drive Florham Park 7932 NJ
   Company Phone Number: 441-8120   Stock Exchange / Ticker: NASDAQ CLRB


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Stocks on the Move

Cellectar Biosciences Navigating Regulatory Milestones Amidst Market Turbulence

Published Tue, Aug 6 2024 9:32 PM UTC

''Cellectar Biosciences Inc. (NASDAQ: CLRB) finds itself at a critical juncture as various news reports illuminate a complex landscape of opportunities and challenges. Recent developments surrounding its lead therapy candidate, iopofosine I 131, highlight both the promise of regulatory advancements and the turbulence that accompanies market fluctuations.On July 23, 2024, Cel...

Shares

Cellectar Biosciences Secures $19.4 Million and Sets Path for Potential $73.3 Million in Funding to Advance Revolutionary Cancer Treatment Initiatives

Published Mon, Jul 22 2024 10:40 AM UTC

Cellectar Biosciences Announces Successful Exercise of Tranche B Warrants and Potential for Additional Funding of up to $73.3 Million
FLORHAM PARK, N.J., July 22, 2024 - Cellectar Biosciences, a prominent late-stage clinical biopharmaceutical company specializing in the creation, development, and commercialization of innovative cancer treatment drugs, has recently reveal...

Cellectar Biosciences Inc

Cellectar Biosciences Inc Faces Growing Concerns with Operating Deficit in Q1 2024

The recent financial reports of Cellectar Biosciences Inc are raising concerns among stakeholders and shareholders, as the company's performance continues to decline. During the first quarter of 2024, the company recorded a net shortfall of $-21.582 million, compared to no deficit in the same period last year. This significant drop in profits highlights the company's struggles in their current operations.
Furthermore, the company recently published an operating deficit of $-12.001486 million, further exacerbating the growing concerns among stakeholders. The continuous decline in financial performance is causing shareholders to question the effectiveness of the current business model at Cellectar Biosciences Inc.

Cellectar Biosciences Inc

Cellectar Biosciences Inc. Stock Soars as Positive Market Sentiment Prevails

Cellectar Biosciences Inc, a late-stage clinical biopharmaceutical company focused on cancer treatment, has seen its stock rise by 20.9% over the last five trading days. This significant increase in stock value indicates a positive market sentiment towards the company. Moreover, over the past 12 months, the stock has shown a continuous upward trend, coming within 9% of its 52-week high.
These positive market indicators could be attributed to recent developments within the company. Cellectar Biosciences announced through a press release that it has achieved positive findings from an investigator-initiated Phase 1 study. The study evaluated the safety and efficacy of Iopofosine in combination with external beam radiotherapy (EBRT) for the treatment of recurrent head and neck cancer. This groundbreaking research has created a sense of hope for both patients and healthcare professionals who are seeking improved therapeutic options for this challenging disease.

Clinical Study

Breaking New Ground: Iopofosine Combination Therapy Shows Promise in Recurrent Head and Neck Cancer Treatment.

Published Mon, Mar 4 2024 11:40 AM UTC

In a recent press release, Cellectar Biosciences, a renowned biopharmaceutical company, announced positive findings from an investigator-initiated Phase 1 study evaluating the safety and efficacy of Iopofosine in combination with external beam radiotherapy (EBRT) for the treatment of recurrent head and neck cancer. This groundbreaking research brings new hope to patients and...










Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com